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Abstract
Background: Epithelial ovarian cancer is a significant cause of mortality both in the United States and worldwide, due
largely to the high proportion of cases that present at a late stage, when survival is extremely poor. Early detection of
epithelial ovarian cancer, and of the serous subtype in particular, is a promising strategy for saving lives. The low prevalence
of ovarian cancer makes the development of an adequately sensitive and specific test based on blood markers very
challenging. We evaluated the performance of a set of candidate blood markers and combinations of these markers in
detecting serous ovarian cancer.
Methods and Findings: We selected 14 candidate blood markers of serous ovarian cancer for which assays were available to
measure their levels in serum or plasma, based on our analysis of global gene expression data and on literature searches. We
evaluated the performance of these candidate markers individually and in combination by measuring them in overlapping
sets of serum (or plasma) samples from women with clinically detectable ovarian cancer and women without ovarian
cancer. Based on sensitivity at high specificity, we determined that 4 of the 14 candidate markers-MUC16, WFDC2, MSLN
and MMP7-warrant further evaluation in precious serum specimens collected months to years prior to clinical diagnosis to
assess their utility in early detection. We also reported differences in the performance of these candidate blood markers
across histological types of epithelial ovarian cancer.
Conclusions: By systematically analyzing the performance of candidate blood markers of ovarian cancer in distinguishing
women with clinically apparent ovarian cancer from women without ovarian cancer, we identified a set of serum markers
with adequate performance to warrant testing for their ability to identify ovarian cancer months to years prior to clinical
diagnosis. We argued for the importance of sensitivity at high specificity and of magnitude of difference in marker levels
between cases and controls as performance metrics and demonstrated the importance of stratifying analyses by histological
type of ovarian cancer. Also, we discussed the limitations of studies (like this one) that use samples obtained from
symptomatic women to assess potential utility in detection of disease months to years prior to clinical detection.
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Introduction
Epithelial ovarian cancer (EOC) has the highest mortality of all
gynecological cancers and is the fifth leading cause of cancer death
among women in the United States. In 2007, there were 22,430
new cases of EOC and an estimated 15,280 deaths in the United
States [1]. The five year survival rate for EOC in the US is
approximately 45%, due largely to the high proportion of EOCs
that are not detected until they have spread outside the ovary [2].
There are four major histological types of EOC: serous,
endometrioid, clear cell, and mucinous. These four histological
types are enormously different, in both clinical and molecular
characteristics. The serous subtype is the most commonly
diagnosed and is responsible for most ovarian cancer deaths [2].
Early detection is a promising approach to reducing mortality
from cancers that are most often diagnosed in their late stages [3].
Because the histological types of ovarian cancer are intrinsically
different diseases, the optimal strategies for early detection, and
the cost-benefit calculations in evaluating their performance, may
be different for each subtype. The potential benefit of early
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2633detection is greatest for serous EOC because it is the most
common and lethal ovarian cancer subtype, and it has therefore
been the primary target of our efforts.
The clinical utility of a diagnostic test is often expressed in terms
of positive predictive value (PPV)–the fraction of test positives that
are true positives. To be justified for clinical use, a diagnostic test
must achieve a PPV that balances the benefits of early detection
against thecost ofthetest andrisk associated withfalsepositives(e.g.
anxiety, unnecessary surgery). A PPV of at least 10%, meaning that
10% of women that test positive actually have the disease, has often
been used as a somewhat arbitrary target for an early detection test
for ovarian cancer [4]. A major factor in the challenging nature of
early detection of serous EOC is the low incidence of the disease in
the general population, which implies that a screening test must be
highly specific in order to avoid over-diagnosis and over-treatment.
In the general population, to achieve a PPV of 10%, the
performance requirements are extremely high: given the age-
adjusted annual incidence rate of all EOC in women over age 50 in
the US of 35 per 100,000 [5], a test must achieve 99.7% specificity
at 80% sensitivity. The specificity required for selective detection of
the serous subset of EOC in the general population (which has a
lower incidence than the figure above) would be correspondingly
higher. In order to achieve a PPV of 10% for detecting serous EOC
among BRCA1 mutation carriers, a test must achieve a specificity
requirement of 78.1% at 80% sensitivity given the incidence of
serous ovarian cancer over age 50 in this population is
approximately 3000 cases per 100,000 [6]. One must bear in
mind, however, that this performance could be achieved through
the combined performance of a blood test as a first-line screen and
follow-up imaging test. Furthermore, the threshold for an
acceptable PPV depends on the intervention and it may be that a
PPV less than 10% could be acceptable.
The best-studied serum marker for ovarian cancer, CA125
(MUC16), has been evaluated extensively for its utility as a marker
of ovarian cancer, and is FDA approved for recurrence monitoring.
In retrospective studies, CA125 has been shown to signal disease
recurrence roughly six months prior to the development of
symptoms [7]. In women with clinically detected stage I EOC (of
various histologies), pre-operative serum levels of CA125 are
elevated (.35 U/ml) in roughly 66% of women [8]. In the Janus
longitudinal cohort, CA125 has been shown to contain potential
signals intheblood asearlyasfive yearsbeforeclinicaldetection[9],
and to have an estimated sensitivity of 45% at 93% specificity at 1.5
yearsprior todiagnosis amongwomenover 50years ofage,which is
encouraging but far from adequate for clinical use [10].
These results provide an important example of the difference in
marker performance in clinically diagnosed disease versus pre-
symptomatic disease–the true target of an early detection test. The
reduction in performance from clinically diagnosed tumors (even
Stage I) to pre-symptomatic disease is not surprising given that
clinically diagnosed cancers are almost certainly in general much
larger than the early tumors we need to detect to improve survival,
and underscores the importance of evaluating candidate markers
in specimens from pre-symptomatic women. Unfortunately, due to
limitations in specimen availability, most studies of marker
performance (including this one) have evaluated performance in
clinical samples collected from women who already have signs and
symptoms of cancer.
In recent years, the application of genomic and proteomic
technologies has fueled an explosion in marker discovery efforts in
various diseases, including EOC. Some studies have evaluated
combinations of two or more markers in order to identify the sets
that work best together in a panel. Such studies are essential
because it is unlikely that any single marker will have adequate
performance in detecting cancers prior to the development of
symptoms. While evaluation of a candidate marker’s contribution
to a panel in specimens from women with clinically apparent
ovarian cancer may be a poor predictor of its lead time and utility
in early detection, it provides a useful filter for gaining access to
precious pre-clinical specimens.
We undertook a systematic performance evaluation of 14
candidate blood-based markers for EOC selected based on a gene
expression data and published literature. Our candidate marker
list included: MUC16 (CA125), WFDC2 (HE4), MSLN, IGF2,
CHI3L1 (YKL40), MMP7, MIF, PRL, SPP1 (OPN), BMP7,
LCN2, IL13RA2, TACSTD1 (EpCam), and AMH. Note that all
markers were referred to by their HUGO gene symbols. We
evaluated these markers using common sets of well annotated
EOC cases and control serum samples, including women with
healthy ovaries as well as women with benign and malignant
ovarian conditions. Our objective was to use performance in these
clinically diagnosed cases as a filter to assess which candidate
markers warranted further evaluation in precious serum specimens
obtained months to years prior to diagnosis of ovarian cancer. We
also used these data to conduct analyses of marker panels (a named
group of markers) and composite markers (which include a specific
classification or combination rule) as well as to explore the effect of
stratifying analyses by histological type.
Results
Marker Selection
We selected candidate markers by using gene expression data to
identify genes highly expressed in ovarian cancer but not in the
rest of the body, as described in Materials and Methods. Using this
strategy, the following candidate markers with commercially
available ELISAs or other published assays were selected for
testing: MSLN, WFDC2, IGF2, CHI3L1, MMP7, BMP7, LCN2,
TACSTD1. Many of these markers have previously been reported
to be elevated in women with ovarian cancer [11–22]. Several
other candidate markers were also tested based on literature and/
or collaborative opportunities: MUC16, IL13RA2, PRL, MIF,
SPP1 and AMH [8,23–25].
Evaluation of individual markers
In order to optimize analysis of marker combinations, we
evaluated each candidate marker in common sets of well
annotated EOC cases and control serum samples, including
women with healthy ovaries, as well as women with benign and
malignant ovarian conditions. The 14 candidate markers for EOC
described above were evaluated in a stepwise manner using three
overlapping serum sets of increasing complexity: the Filtering set,
Mini-Triage set, and Triage set (Table 1). The composition of
each of the serum sets with regard to stage and tumor histology is
described in Table 2.
The first step of candidate marker evaluation was the Filtering
set of sera, a series of mixtures in varying ratios of pooled EOC
sera from EOC patients and control serum pools from volunteers
who did not have EOC. This test served as a first cut to eliminate
assays that did not show a consistent difference between cases and
controls with minimal use of case and control specimens. This
filter was essentially an endogenous standard curve; failure to show
a linear relationship between case to control ratio and ELISA
signal indicated either that marker levels were roughly the same in
most cases as in controls or that the assay was not sensitive enough
to detect a small increase (or decrease) in marker levels in cases.
Eight of the 11 candidate markers tested in the filtering set showed
a linear relationship between the ratio of EOC patient serum to
Ovarian Cancer Blood Markers
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corresponding ELISA assay, while three of the candidate markers
(TACSTD1, AMH, IL13RA2) showed no consistent relationship
between these values and were not evaluated further.
The eight markers that passed analysis in the Filtering set, as
well as two previously validated EOC markers (MUC16 and
MSLN [17,26]), were further tested in the Mini-Triage serum set
(n=71). Four markers (PRL, SPP1, BMP7, LCN2) showed poor
performance (sensitivity ,10% at 98% specificity and area under
curve (AUC),0.70) in the Mini-Triage set and were not pursued
further. The remaining six candidate markers, as well as previously
validated EOC marker WFDC2 [12,27], were tested in the larger
Triage serum set (n=214). Markers tested on this expanded
dataset were assessed by a number of criteria, including sensitivity
at 98% specificity, AUC, and mean normalized serum marker
levels in specific subsets of cases and controls (Table 3). The known
markers MUC16, WFDC2, and MSLN showed the best
performance according to 98% specificity for all cases versus all
controls, with sensitivities of 70%, 61%, and 30%, respectively.
These three markers also showed the best performance when only
cases of serous histology were considered (sensitivities at 98%
specificity of 86%, 75%, and 45%, respectively). For each marker,
we also calculated the distance between EOC patients and
Healthy Controls (women enrolled in prospective screening trials
who remained free of ovarian cancer for at least two years after
serum collection.) by normalizing all measurements to the mean
levels in these healthy specimens (see Statistical Methods). With
this normalization, the mean level among the case group
represented a ‘‘discriminatory distance’’ measure that reflected
how far the average case was from the average healthy control.
MUC16 and WFDC2 were clearly superior according to this
metric, with mean normalized serum marker concentrations in
cases (relative to Healthy Controls) of 6.7 and 10.0, respectively.
By comparison, the other markers all scored less than 2.5 (Figure 1
and Table 3).
Evaluation of combination markers
For the seven markers evaluated in the Triage set, we tested all
markers in combinations of either two or three, and compared
individuals without cancer to all ovarian cancer patients or serous
cases only. The best-performing two-marker combination in either
analysis was MUC16 and WFDC2 (Table 4). This two-marker
combination yielded sensitivities at 98% specificity of 72% for all
Table 2. Stage and histology of ovarian cases in each serum set.
Filtering Set
Stage Serous Clear Cell Endometrioid Mucinous Adeno.NOS
a Total
I 000 0 00
II 000 0 00
III 30 2 2 0 3 37
IV 901 0 111
None 100 0 12
Total 40 2 3 0 5 50
Mini-Triage Set
Stage Serous Clear Cell Endometrioid Mucinous Adeno.NOS
a Total
I 322 0 18
II 102 0 14
III 11 2 1 1 4 19
IV 101 0 24
Total 16 4 6 1 8 35
Triage Set
Stage Serous Clear Cell Endometrioid Mucinous Adeno.NOS
a Total
I 752 5 423
II 202 0 04
III 32 0 1 1 5 39
IV 301 0 15
Total 44 5 6 6 10 71
aAdenoNOS=Adenocarcinoma Not Otherwise Specified
doi:10.1371/journal.pone.0002633.t002
Table 1. Marker evaluation pipeline: cases and controls.
Patient Class
Filtering
Set
Mini-Triage
Set Triage Set Overlap
a
Ovarian Cancer Cases 50 35 71 17
Healthy Controls
b 9 1 25 81 2
Surgical Benigns
c 0 1 65 31 6
Surgical Normals
d 083 2 8
Total 59 71 214
a)Overlapping specimens in the Mini-Triage and Triage sets
b)Healthy Controls: women enrolled in prospective screening trials who
remained free of ovarian cancer for at least two years after serum collection.
c)Surgical Benigns: women with surgically confirmed benign ovarian pathology.
d)Surgical Normals: women that underwent surgery but no ovarian pathology
was identified.
doi:10.1371/journal.pone.0002633.t001
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98% specificity for MUC16 alone of 70% (all cases) and 86%
(serous cases). However, the performance of the best two marker
combination (MUC16 and WFDC2) was not significantly different
from the best single marker (MUC16) as measured by pAUC
(from specificity=100% to specificity=90%) between the best
single marker and the best two marker combination. Evaluation of
all potential three-marker combinations (data not shown) also
failed to show any improvement in performance in either
sensitivity at 98% specificity or AUC.
Performance evaluation in the context of histological
type and stage
To investigate how marker performance varied with histological
type and stage, we calculated the number and percentage of cases
correctly classified by the MUC16/WFDC2 combination marker
by histology and stage, for all cases versus all controls (Healthy
Controls, Surgical Benigns, and Surgical Normals–see Clinical
Blood Specimens) in the Triage set using 98% specificity for this
combination marker. The performance of the MUC16/WFDC2
combination marker clearly varied with ovarian cancer histology:
the percentage of cases correctly classified was 86% (38/44) for
serous cases, 83% (5/6) for endometrioid cases, 17% (1/6) for
mucinous cases and 0% (0/5) for clear cell cases (Table 5). Other
markers whether used alone, in pairs, or combinations of three,
showed similarly poor performance in clear cell and mucinous
cases (data not shown).
Marker performance also appeared to vary with stage–the
MUC16/WFDC2 combination marker correctly identified 39%
(9/23) of Stage I cases, 75% (3/4) of Stage II cases, 87% (34/39) of
Stage III cases and 100% (5/5) of Stage IV. However, these results
are confounded by the different mix of histologies across stages. In
the Triage set, the majority of stage III and IV cases were serous
cancers (35/44), while the majority of stage I and II cases were
non-serous cancers (endometrioid, mucinous, clear cell and other)
(18/27). This sample composition reflected the fact that serous
cancers are more likely to be identified at a late stage, while the
reverse is true for endometrioid, clear cell and mucinous cancers.
Discussion
We evaluated 14 candidate early detection markers for EOC
using three overlapping sets of serum samples collected from
women with clinically diagnosed EOC and cancer-free women
with and without gynecological diseases. Markers were evaluated
in successively larger serum sets depending on their performance
at the previous step. For markers that graduated to the largest
sample set, we evaluated the performance of each marker
individually and in combinations of two or three for their ability
to detect clinically diagnosed ovarian cancer.
Three assays (TACSTD1, AMH, IL13RA2) failed to detect the
corresponding marker in pooled sera from EOC cases or pooled
control sera. These results suggest that if there is a difference
between cases and controls for these markers it must be very small
and we would need a more sensitive assay to detect the difference.
Four markers: PRL, SPP1, BMP7 and LCN2, passed the Filtering
set (pools of cases and controls) but had poor sensitivity and
specificity when evaluated in individual case and control
specimens. A further evaluation of PRL in a serum set containing
more surgical controls revealed that the elevated serum PRL levels
were related to the blood collection conditions rather than to
disease state [28]. These observations underscore the importance
Figure 1. Normalized serum marker levels. Bar heights indicate
the mean of the normalized values of a given marker in the specified
subset of cases or controls. Error bars represent the 95% confidence
interval associated with the mean. The logarithm of serum marker
concentrations were normalized to standard deviations from the mean
of the corresponding measurements in Healthy Controls.
doi:10.1371/journal.pone.0002633.g001
Table 4. Combination marker performance.
All Cases (N=71) Serous Cases (N=44)
Gene Symbol Sens98
a AUC
b P-value
c Sens98
a AUC
b P-value
c
MUC16 70% 0.92 N/A 86% 0.98 N/A
MUC16+WFDC2 72% 0.92 0.342 86% 0.99 0.187
MUC16+WFDC2+MSLN 72% 0.91 1.000 86% 0.99 1.000
MUC16+WFDC2+MIF 72% 0.93 0.396 86% 0.99 1.000
MUC16+WFDC2+IGF2 72% 0.94 0.353 86% 0.99 1.000
MUC16+WFDC2+MMP7 72% 0.91 0.748 86% 0.99 1.000
MUC16+WFDC2+CHI3L1 72% 0.92 1.000 86% 0.99 1.000
a)Sens98=Sensitivity at 98% specificity in discriminating cases from all controls (Healthy Controls, Surgical Benigns and Surgical Normals).
b)AUC=Area Under (ROC) Curve for discriminating cases from all controls (Healthy Controls, Surgical Benigns and Surgical Normals).
c)P-value for the best available two-marker combination compared to the best available three-marker combination (see Materials and Methods).
doi:10.1371/journal.pone.0002633.t004
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careful selection of controls, as some groups continue to report that
prolactin is a useful marker of ovarian cancer without adequate
attention to the matching of controls [29].
We found that marker levels varied considerably among
histological types and clinical stages of ovarian cancer. All of the
markers and combinations in this analysis had higher sensitivity at
98% specificity when only the serous EOC cases were considered,
as compared to all cases of EOC. This difference appeared to be
due to the poor performance of our candidate markers in clear cell
and mucinous cases. In terms of sensitivity at 98% specificity, the
best performing markers for the detection of clinically apparent
serous EOC were MUC16, WFDC2 and MSLN, with sensitivities
at 98% specificity of 86%, 75%, and 45%, respectively, in the
Triage set of serum samples. No combination of markers provided
a significantly better sensitivity at 98% specificity than the best
individual marker, MUC16, in distinguishing all ovarian cancers
or serous ovarian cancers from controls. The high positive
correlation (range: 0.54–0.75) among the three best performing
single markers contributed to the lack of significant improvement
in sensitivity when combining markers in this study.
Our data analysis approach differed from those in most previous
studies in several significant ways. First, we stratified our results by
histological type, with an emphasis on serous EOC. Ovarian
cancers of different histological types are well known to have very
different clinical and molecular characteristics, yet they are often
erroneously grouped together in analyses of marker performance,
presumably for the sake of greater sample size. We focused our
analyses on the serous subtype of EOC because early detection of
high-grade serous cancers has the greatest potential to save lives.
This decision to stratify was supported by our finding that the
markers examined here consistently performed better in serous
and endometrioid cases than in clear cell and mucinous cases (even
in Stage I cases only), and consequently that marker performance
was lower in a pooled case set than in serous cases alone. Second,
we elected not to stratify our analysis by stage of disease, as we are
not confident that clinical Stage I/II high grade serous cancer is a
useful model for the clinically occult precursors to lethal ovarian
cancers which are the true targets of early detection. Furthermore,
the distribution of histologies varied with stage, confounding
interpretation of stage-specific results. Third, we chose to use
unconventional measures of marker performance. The low
prevalence of EOC requires a highly specific marker to reduce
the risk of false positives in healthy women so as to avoid
unnecessary distress, diagnostic follow-up and surgery. By contrast,
the conventional AUC analysis indiscriminately summarizes the
performance of a marker at all levels of specificity. Although we
have included AUC values in this report, we consider the
sensitivity of an assay at 98% specificity to be a more salient
measure of its performance. We recognize, however, that even
with superlative sensitivity, 98% specificity is still not sufficient for
an early detection test in a normal-risk population.
Finally, we included a measure of magnitude of difference in
signal between EOC patients and apparently healthy volunteers.
We believe this metric is useful for helping to predict the value of a
marker for early detection when using clinically detected cases
because high signal at the time of symptoms may be consistent
with discernible signal earlier in the course of the disease when
tumor burden is lower and signal is presumably lower. MUC16
and WFDC2 were the only markers that showed large elevations
in cases relative to Healthy Controls (6.7 and 10.0 discriminatory
distance units, respectively). Markers having the same sensitivity
and specificity can have very different discriminatory distance
measures, and those with greater distance may be better
candidates for early detection applications because they may
maintain their performance better with smaller tumor burdens as
marker levels attenuate toward control levels.
An important factor to consider in interpreting our results and
other similarly designed studies is that these markers were
evaluated based on their ability to distinguish between serum
specimens from women with and without clinically apparent
ovarian cancer. It is crucially important to keep in mind that the
value of a marker for early detection is determined by its ability to
detect ovarian cancer prior to development of clinical signs or
symptoms (and, moreover, prior to progression to an advanced
stage). Thus, until the performance of a candidate marker is
evaluated with specimens from women with asymptomatic, early
stage cancer, its value as an early detection marker remains
hypothetical, and researchers must be cautious not to overstate
their claims when assays have only been tested on samples from
women with clinically detectable disease [29]. Furthermore, the
relationship between marker performance in specimens collected
at the time of diagnosis to performance during the window of
opportunity for early detection is not well understood, and may
vary considerably among markers.
The results presented here are encouraging, but much more
work needs to be done before we will know whether we are in
range of an effective early detection test for EOC. Specifically, it
will be essential to evaluate markers in serum samples obtained
prior to disease detection, in samples from women with clinically
occult, localized serous cancers. Samples collected prior to disease
diagnosis are a limited and precious resource, and samples from
women with unsuspected, occult, localized cancers (e.g., discov-
ered at risk reducing salpingo-oophorectomy) are even more
precious, so careful selection of the markers worthy of evaluation
in these samples is critical. Given the uncertain relationship
between marker performance prior to diagnosis and performance
at or after diagnosis of ovarian cancer, we believe that markers
Table 5. Summary of correctly identified cases by histological type.
Stage 1 Stage II Stage III Stage IV Total
Serous 86% (6/7) 50% (1/2) 88% (28/32) 100% (3/3) 86% (38/44)
Endometrioid 50% (1/2) 100% (2/2) 100% (1/1) 100% (1/1) 83% (5/6)
Mucinous 20% (1/5) N/A (0/0) 0% (0/1) N/A (0/0) 17% (1/6)
Clear Cell 0% (0/5) N/A (0/0) N/A (0/0) N/A (0/0) 0% (0/5)
Other 25% (1/4) N/A (0/0) 100% (5/5) 100% (1/1) 70% (7/10)
Total 39% (9/23) 75% (3/4) 87% (34/39) 100% (5/5) 72% (51/71)
doi:10.1371/journal.pone.0002633.t005
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complement MUC16 in clinical (at-diagnosis) samples should not
be excluded from further evaluation. We therefore intend to
proceed with evaluation of MUC16, WFDC2, MSLN and MMP7,
all of which have sensitivity .30% at 98% specificity in detection
of clinically apparent serous cancers, beginning with analysis of
serum specimens collected months to years prior to diagnosis of
serous ovarian cancers.
Future work toward early detection of serous ovarian cancer
may also benefit from expanded discovery efforts. Recent studies
of the early natural history of EOC suggest that some cases of
serous EOC may originate in the fallopian tubes (FT). In women
with a germline mutation in BRCA1 or BRCA2, occult
malignancy of serous histology, intraepithelial carcinoma or
dysplasia is frequently found in the fimbrial end of the FT at the
time of prophylactic surgery [30,31]. In fact, prophylactic removal
of fallopian tubes and ovaries in women at genetically high risk of
EOC is a proven strategy for reducing mortality from ovarian
cancer. In light of these findings, it may be useful to consider genes
highly and specifically expressed in early stage serous fallopian
tube cancers as potential markers of serous ‘ovarian’ cancer
(whereas previous efforts focused on late stage ovarian tumors). In
addition, advances in proteomic technologies have made it
possible to do in-depth profiling of serum proteins, which, if
applied to pre-diagnostic specimens could prove to be an effective
means of identifying relevant markers. Ongoing efforts using
targeted discovery, thoughtful combination of markers, and
stratification of screening populations by cancer risk may yet lead
to an effective early detection test for ovarian cancer.
Materials and Methods
Marker selection
The goal of our marker selection was to identify genes whose
protein products are consistently found at higher levels in the
blood of patients with early stage serous ovarian cancer than in
healthy individuals. Our general strategy for achieving this goal
was to identify genes that were highly expressed in serous ovarian
cancers but minimally expressed in most normal tissues. We
further favored genes that were known to encode secreted
proteins. The gene expression data used to estimate gene
expression in ovarian tumors included cDNA microarray profiles
of 72 ovarian tumors, of which most were late stage tumors of
serous histology (manuscript in preparation). Data on gene
expression (as reflected by mRNA levels) in normal tissues were
obtained from a published study of 115 human tissue samples
representing 35 different tissue types, using cDNA microarrays
representing approximately 26,000 different human genes [32].
Based on these criteria, the following candidate markers with
available serum assays were selected for testing: WFDC2, MSLN,
IGF2, CHI3L1, MMP7, BMP7, LCN2, TACSTD1. Several other
markers were also tested based on literature and/or collaborative
opportunities: MUC16, IL13RA2, PRL, MIF, SPP1 and AMH
[8,23–25].
Clinical blood specimens
Study participants were recruited between June 1 1998 and July
1 2002 to support protocols of the Pacific Ovarian Cancer
Research Consortium (POCRC) by physicians at Pacific Gyne-
cology Specialists, Swedish Medical Center, Providence Medical
Center, the University of Washington/Seattle Cancer Care
Alliance, and Virginia Mason Medical Center. Cases were defined
as having invasive epithelial carcinoma confirmed by standardized
review of medical records and pathologist examination of paraffin-
embedded tissue for tumor histology. FIGO stage and histology of
the cases are summarized in Table 2. Blood was also obtained
from three categories of controls: i) ‘‘Healthy controls’’-apparently
healthy women enrolled in prospective screening trials who
remained free of ovarian cancer for at least two years after serum
collection; ii) ‘‘Surgical Benigns’’–women with surgically con-
firmed benign ovarian pathology ii) ‘‘Surgical Normals’’–women
that underwent surgery but no ovarian pathology was identified
(Table 1). Each patient provided written informed consent and a
medical records release form approved by the FHCRC institu-
tional review board (IR file number #4771). Surgical specimens
were obtained prior to any treatment or surgery (but after the
administration of anesthesia). All specimens were anonymized for
patient confidentiality.
Blood was drawn into three or four 10.0 ml SST (serum
separator) Vacutainer blood collection tubes (Fisher Scientific Cat.
# 02-683-98, Mfg. No.: 367985) as well as one lavender-top
EDTA Vacutainer blood collection tube (Fisher Scientific Cat. #
02-657-32). Blood was processed and placed in the freezer within
4 hours of the collection time. All tubes were spun in a balanced
centrifuged at 1,2006g for 10 minutes to separate serum from
cellular components the cells from the fluid. Serum from the SST
tubes and plasma from the EDTA tube were aliquoted into
microcentrifuge tubes at 1 ml per aliquot and stored at 280uC. All
markers were evaluated with serum with the exception of SPP1
(osteopontin) which was evaluated using EDTA plasma as per
manufacturer’s instructions (see Table 6).
Markers were evaluated using three overlapping sets of blood
specimens, detailed in Table 1. (1) The Filtering set comprised a
series of mixtures of two pools of serum samples from (a) 50 late
stage EOC patients and (b) 9 age-matched apparently healthy
women. The case and control sera were serially diluted to create a
series of samples with defined ratios (fraction of case pool/
total=1/1, 1/2, 1/4, 1/8, 1/16, 1/32, 1/64, 1/128) of case and
control pooled patient serum. We used the Filtering set to test for a
difference in marker levels between case and control pools as
measured by a linear relationship between the relative ratio of
cases to controls and the immunoassay signal. Prior to testing in
the filtering set, assays were evaluated with manufacturer supplied
standard curves to assess limits of detection. (2) The Mini-Triage
set comprised serum samples from 71 women, including patients
with different histological types and stages of EOC, women with
benign ovarian tumors (Surgical Benigns), women with healthy
ovaries undergoing surgery for other gynecologic conditions
(Surgical Normals), and age-matched women enrolled in prospec-
tive screening trials who remained free of ovarian cancer for at
least two years after serum collection (Healthy Controls). This set
of samples provided a preliminary estimate of the specificity and
sensitivity of each immunoassay. (3) The Triage set consisted of an
expanded set of 214 serum samples including specimens from 71
EOC patients (various histologies), and greater numbers of
Healthy Controls, Surgical Benigns, and Surgical Normals. The
Triage set had 17 cases and 36 controls in common with the Mini-
Triage set. The Triage set was selected subsequent to the Mini-
Triage, as some specimens did not have sufficient volume
remaining for further testing after being used in the Mini-Triage
set. Specimen aliquots used in the Triage and Mini-Triage sets
were delivered to laboratories separately in a blinded fashion and
were tested independently. The Triage set served as an in-depth
verification of results in the from the Mini-Triage set. Table 1
describes the case/control composition of each serum set while
Table 2 describes the breakdown of cases by stage and histology
for each set.
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Serum levels of MUC16, WFDC2 and MSLN were measured
using bead-based immunoassay consistent with previously pub-
lished methods [27,28,33] (Table 7, Table S1). The mAbs were
dialyzed against Dulbecco’s phosphate buffered saline (PBS)
(Invitrogen Corporation, Carlsbad, CA) when necessary. Detec-
tion antibodies were biotinylated using the EZ-Link-sulfo-NHS-
biotinylation kit (Pierce, Rockford, IL) and dialyzed (G Biosciences
Tube-O-Dialyzer, 4kDa MWCO) against PBS. Carboxy-coated
microspheres were coupled with capture antibody, using the
appropriate coupling buffers. Assays were performed in 96-well
filter plates (Millipore Corporation, Billerica, MA) with a vacuum
manifold (Millipore) for wash steps and to drain reagents.
Incubations were performed at room temperature in the dark on
a plate shaker. Serum samples were diluted and added to each well
containing beads coupled with the relevant capture antibody. After
incubation, plates were washed and the biotinylated detection
antibody was added, followed by phycoerythrin-conjugated
streptavidin. The median fluorescence intensity (MFI) of approx-
imately 100 microspheres from each sample was analyzed with the
Bio-Plex Array reader (Bio-Rad). Eight replicates of an interme-
diate serum pool made up of 1 part case and 3 parts control serum
pools were included on each plate. Readings from patient samples
were transformed by dividing by the average MFI of the
intermediate pool replicates included on the same plate. Separate
experiments showed that this procedure reduces plate-to-plate
variation in the results (data not shown).
The levels of remaining candidate markers in serum or plasma
samples were measured by ELISA using kits obtained from
commercial suppliers or collaborators (MIF assay was kindly
provided by Elliot Segal) according to manufacturers’ instructions
(Table 6, Table S2). Briefly, freshly thawed serum was diluted with
dilution buffer and added to each well. After incubation, plates
were washed and incubated with conjugated secondary antibody.
Antibody/enzyme conjugates were detected by addition of
substrate. Reactions were stopped and optical density was
determined using a Spectra Max M2 Microplate Reader
(Molecular Devices) at 450 nm or 405 nm with the appropriate
baseline correction for each assay. The concentration of each
marker was determined using a standard curve that was
constructed by plotting the mean optical density obtained for
each reference standard provided by the kit against the known
concentration. Each sample was tested in duplicate. Laboratories
performing the immunoassays were blinded with respect to the
case/control status of serum and plasma samples.
Statistical Methods
Receiver operating characteristic (ROC) curve methods were
used to quantify marker performance both graphically and
statistically [34]. In order to enable comparison of markers that
are measured on different scales, we first transformed all markers
(e.g., by their logs) so that the values in the control group appeared
normally distributed, and re-scaled so that the Healthy Controls
(apparently healthy women followed for at least two years) had a
Table 6. Commercial ELISA reagents.
Gene Symbol Alias Name Assay Source
a Sensitivity (ng/ml)
AMH MIS anti-Mullerian hormone DSL 0.01
BMP7 bone morphogenetic protein 7 RayBio 20
CHI3L1 YKL-40 chitinase 3-like 1 Quidel 1.67 (U/ml)
IGF2 insulin-like growth factor 2 DSL 0.002–0.058
IL13RA2 interleukin 13 receptor, alpha 2 Anogen 0.0005–0.004
LCN2 MMP-9; NGAL lipocalin 2 R&D Systems 2.2
LCN2 MMP-9; NGAL lipocalin 2 Ab Shop 0.11
MIF macrophage migration inhibitory factor Onco Detectors 0.14
MMP7 matrix metallopeptidase 7 R&D Systems 0.1
PRL Prolactin DSL 0.016
SPP1 Osteopontin secreted phosphoprotein 1 Assay Designs 10
TACSTD1 Ep-CAM tumor-associated calcium signal transducer 1 BioVendor 0.017
a)All assays were conducted on serum with the exception of SPP1 which was conducted using plasma-EDTA. See Table S2 for catalogue numbers.
doi:10.1371/journal.pone.0002633.t006
Table 7. Bead-based immunoassay reagents.
Target Protein Capture Reagents Detection Reagents
Gene
Symbol Alias Antibody Type Source Antibody Type Source
MUC16 CA125 anti-CA125 X306 mAb Research Diagnostics, Inc. anti-CA125 X52 mAb Research Diagnostics, Inc.
WFDC2 HE4 anti-HE4 2HS mAb Dr. Ingegerd Hellstro ¨m anti-HE4 3D8 mAb Dr. Ingegerd Hellstro ¨m
MSLN Mesothelin anti-MSLN 4H3 mAb Dr. Ingegerd Hellstro ¨m anti-MSLN ovcar569 mAb Dr. Ingegerd Hellstro ¨m
doi:10.1371/journal.pone.0002633.t007
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markers does not affect the ROC curves for individual markers but
facilitates the comparison of markers because of the uniformity of
units of measurement (i.e. the number of standard deviations
above the average healthy subject) [26].
Individual markers were ranked by their sensitivity at high
specificity in comparing cases to all controls (Healthy Controls,
Surgical Benigns and Surgical Normals). We combined markers
using approaches that did not require statistical fitting because of
the low sample sizes. Application of statistical fitting procedures
could have resulted in large biases in biomarker performance. To
combine markers, we restricted attention to rules in which
elevation of any marker above its respective threshold constitutes
a positive result (e.g., an ‘‘or’’ rule). Because all markers were on
the same scale, this ‘‘or’’ rule was implemented by using the
maximum score of the individual markers in the combined set. For
example, consider a patient with normalized MUC16=3.67 and
normalized WFDC2=6.85, meaning that they are 3.67 and 6.85
standard deviations above the mean of the Healthy Controls. The
MUC16/WFDC2 combination marker value for this patient is
6.85, the maximum of 3.67 and 6.85. ROC curves may then be
calculated from these maximum values. ROC curves, area under
the ROC curve (AUC) and partial area under the ROC curve-
from specificity=100% to specificity=90%- (pAUC) were
calculated for all possible combinations of two or three markers.
Combination markers were ranked by the estimated sensitivity at
98% specificity. We also reported for each candidate marker a
measure of the ‘‘discriminatory distance’’, which indicated how far
the marker levels in the average case were from the average
healthy control.
Statistical analyses comparing the pAUC of the most highly
ranked markers and combinations of markers were performed
using a permutation test [36]. To estimate the distribution of the
difference in pAUC under the hypothesis of equality of
distribution of the two markers to be tested, we converted data
from two markers or combinations into triplicates of the form
(Status, Marker 1 value, Marker 2 value). For example, consider
an ovarian cancer patient with normalized MUC16=3.67 and
normalized WFDC2=6.85. The corresponding triplicate would
be (Case, 3.67, 6.85). Under the null hypothesis of equality of
distribution, the two markers were exchangeable. Hence, the
permutation distribution was created by choosing a random subset
of data points and exchanging Marker 1 value with Marker 2
value. The remaining triplicates were not altered. Using these new
markers, we calculated the difference in pAUC (from specifici-
ty=100% to specificity=90%). We repeated this procedure 1000
times recording the difference in pAUC for each repetition. The
reported p-value was the percentage of differences in pAUC under
the permutation distribution that were greater than or equal to the
observed difference in pAUC of the original markers.
Supporting Information
Table S1 Detailed assay conditions for in-house bead-based
assays for MUC16 (CA125), WFDC2 (HE4) and MSLN
(mesothelin).
Found at: doi:10.1371/journal.pone.0002633.s001 (0.01 MB
XLS)
Table S2 Detailed assay characteristics and conditions for
commercial ELISAs.
Found at: doi:10.1371/journal.pone.0002633.s002 (0.01 MB
XLS)
Acknowledgments
We thank the Canary Foundation Science Team for helpful discussions.
We also thank Robin Forrest for her contribution to managing the
Translational and Outcomes Research lab and Kathy O’Briant for
managing the Pacific Ovarian Cancer Research Consortium specimen
repository. POB is an investigator of the Howard Hughes Medical
Institute.
Author Contributions
Conceived and designed the experiments: CP NU BHN POB MWM
CWD. Performed the experiments: XD RAS AW MQW LWB. Analyzed
the data: CP NU POB JDT MWM SH. Contributed reagents/materials/
analysis tools: NU NS. Wrote the paper: CP NU BHN POB JDT XD NS
MWM CWD SH.
References
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer Statistics,
2007. CA Cancer J Clin 57: 43–66.
2. Kosary CL (2007) Chapter 16: Cancer of the Ovary. In: Ries LAG, John L,
Young J, Keel GE, Eisner MP, Lin YD, et al. (2007) SEER Survival
Monograph: Cancer Survival among Adults: US SEER Program, 1988–2001,
Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute.
pp 133–144.
3. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, et al. (2003) The case
for early detection. Nat Rev Cancer 3: 243–252.
4. Jacobs I, Stabile I, Bridges J, Kemsley P, Reynolds C, et al. (1988) Multimodal
approach to screening for ovarian cancer. Lancet 1: 268–271.
5. Surveillance, Epidemiology, and End Results (SEER) Program; SEER*Stat
Database: Incidence-SEER 9 Regs Limited-Use, Nov 2006 Sub (1973–2004)-
Linked To County Attributes-Total U.S., 1969–2004 Counties, released April
2007, based on the November 2006 submission.
6. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, et al. (2006) Clinical and
pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and
BRCA2 carriers. Gynecol Oncol 100: 58–64.
7. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, et al. (1983) A
radioimmunoassay using a monoclonal antibody to monitor the course of
epithelial ovarian cancer. N Engl J Med 309: 883–887.
8. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, et al. (2001) OVX1,
macrophage-colony stimulating factor, and CA-125-II as tumor markers for
epithelial ovarian carcinoma: a critical appraisal. Cancer 92: 2837–
2844.
9. Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E (1988) Elevated serum CA
125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of
ovarian cancer. Int J Cancer 42: 677–680.
10. Bjorge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, et al. (2004) BRCA1
mutations in ovarian cancer and borderline tumours in Norway: a nested case-
control study. Br J Cancer 91: 1829–1834.
11. Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, et al. (2004) Early
detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol
22: 3330–3339.
12. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, et
al. (2003) The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.
Cancer Res 63: 3695–3700.
13. Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, et al. (2007) Neutrophil
gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian
cancer: NGAL is associated with epidermal growth factor-induced epithelio-
mesenchymal transition. Int J Cancer 120: 2426–2434.
14. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, et al. (2005) Serum protein
markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102:
7677–7682.
15. Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, et al. (2006)
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2
expression in epithelial ovarian cancer. Mol Cancer Res 4: 283–292.
16. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, et al. (2003)
Gene expression patterns in ovarian carcinomas. Mol Biol Cell 14: 4376–4386.
17. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, et al. (1999) Soluble member(s)
of the mesothelin/megakaryocyte potentiating factor family are detectable in
sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 96:
11531–11536.
18. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, et al. (1999)
Comparative hybridization of an array of 21,500 ovarian cDNAs for the
discovery of genes overexpressed in ovarian carcinomas. Gene 238: 375–385.
Ovarian Cancer Blood Markers
PLoS ONE | www.plosone.org 9 July 2008 | Volume 3 | Issue 7 | e263319. So J, Navari J, Wang FQ, Fishman DA (2004) Lysophosphatidic acid enhances
epithelial ovarian carcinoma invasion through the increased expression of
interleukin-8. Gynecol Oncol 95: 314–322.
20. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, et al. (2006) Overexpression
of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic
marker for reduced survival of patients with epithelial ovarian cancer. Gynecol
Oncol 103: 483–488.
21. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, et al. (2006)
Expression profiling identifies altered expression of genes that contribute to the
inhibition of transforming growth factor-beta signaling in ovarian cancer.
Cancer Res 66: 8404–8412.
22. Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, Wang Y, et al. (1999)
The matrix metalloprotease pump-1 (MMP-7, Matrilysin): A candidate marker/
target for ovarian cancer detection and treatment. Tumour Biol 20: 88–98.
23. Agarwal R, Whang DH, Alvero AB, Visintin I, Lai Y, et al. (2007) Macrophage
migration inhibitory factor expression in ovarian cancer. Am J Obstet Gynecol
196: 348 e341–345.
24. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK (2006) Interleukin-
13 receptor alpha2 chain: a potential biomarker and molecular target for
ovarian cancer therapy. Cancer 107: 1407–1418.
25. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, et al. (2005) BRCA-
mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
Obstet Gynecol 106: 1327–1334.
26. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, et al. (2004)
Combining CA 125 and SMR serum markers for diagnosis and early detection
of ovarian carcinoma. Gynecol Oncol 95: 9–15.
27. Scholler N, Crawford M, Sato A, Drescher CW, O’Briant KC, et al. (2006)
Bead-based ELISA for validation of ovarian cancer early detection markers. Clin
Cancer Res 12: 2117–2124.
28. Thorpe JD, Duan X, Forrest R, Lowe K, Brown L, et al. (2007) Effects of blood
collection conditions on ovarian cancer serum markers. PLoS ONE 2: e1281.
29. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, et al. (2008) Diagnostic
markers for early detection of ovarian cancer. Clin Cancer Res 14: 1065–1072.
30. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, et al. (2002)
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2
mutation. N Engl J Med 346: 1609–1615.
31. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, et al. (2002)
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
N Engl J Med 346: 1616–1622.
32. Shyamsundar R, Kim YH, Higgins JP, Montgomery K, Jorden M, et al. (2005)
A DNA microarray survey of gene expression in normal human tissues. Genome
Biol 6: R22.
33. Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, et al. (2008) Use of
Yeast-Secreted In vivo Biotinylated Recombinant Antibodies (Biobodies) in
Bead-Based ELISA. Clin Cancer Res 14: 2647–2655.
34. Pepe MS (2003) The Statistical Evaluation of Medical Tests for Classification
and Prediction. Oxford, UK: Oxford University Press.
35. Pepe MS, Longton G (2005) Standardizing diagnostic markers to evaluate and
compare their performance. Epidemiology 16: 598–603.
36. Venkatraman ES, Begg CB (1996) A distribution-free procedure for comparing
receiver operating characteristic curves from a paired experiment. Biometrika
83: 835–848.
Ovarian Cancer Blood Markers
PLoS ONE | www.plosone.org 10 July 2008 | Volume 3 | Issue 7 | e2633